USD10
Actions ABOS
À propos de Acumen PharmaceuticalsAcumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
USD10
Actions ABOS
À propos de Acumen PharmaceuticalsAcumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Statistiques
FENÊTRE DE TRADING
Fermé
OUVRE À
Données insuffisantes
Capitalisation boursière
162,48 M $US
PRIX D'OUVERTURE
2,48 $US
BAS (1 an)
0,8551 $US
ÉLEVÉ (1 an)
3,60 $US
BAS (24 h)
2,25 $US
ÉLEVÉ (24 h)
2,55 $US
Volume (24 h)
922,92 k $US
25,52 %
Historique des prix
Time | Price | Change |
|---|---|---|
Aujourd'hui | 2,48 $US | |
1 jour | 2,33 $US | |
1 semaine | 2,80 $US | |
1 mois | 3,16 $US | |
1 an | 1,10 $US |